Ketamine Long Therm Follow Up Study

Five Years Follow up: Add on Intravenous Ketamine for Major Depressive Disorder

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04238039

Acronym

ket_Fol_Up

Enrollment

Registered

2020-01-23

Start date

2019-12-14

Completion date

2020-04-01

Last updated

2020-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Followin Ketamine Treatment

Keywords

Major Depressive Disorder, ketamine, follow up, relapse

Brief summary

Results of the study and of 5 years follow up of depressed patients who participated in the study during 2014-2015. We will locate the participants and will interview them will use the same questionnaires to evaluate their depressive symptoms. We will also measure the time to relapse.

Detailed description

Anamnestic data will be collected from the patients, in addition, depressive symptoms will be measured using Montgomery Asberg Depression Scale (MADRAS). In addition, the Clinical Global Severity Scale (CGI-S) and Clinical Global Improvement (CGI-I) were performed 2 hours after treatment. In addition, we performed to prolong the time to relapse in this patient.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 90 Years

Healthy volunteers

Inclusion criteria

* Participants in the ketamine study

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Time to relapse	5 years	Medications

Countries

Israel

Outcome results